The burgeoning landscape of novel treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar https://socialmediastore.net/story21722245/retatrutide-vs-tirzepatide-a-comparative-analysis